Extraction review
30 candidate(s) · status completed · 2026-06-14 23:04
Review before activation. Approving creates a structured, source-attributed record (asset, dosing reference, or evidence claim). Rejected candidates are discarded. Unreviewed candidates never reach the Copilot or protocol builder.
Candidate assets
9
- TB-500 / TB4conf 90%pending
BPC-157 combined with TB-500 / TB4 supports connective-tissue and tendon recovery.
- BPC-157conf 90%pending
BPC-157 250 mcg subcutaneous twice daily for 4 weeks, then 250 mcg once daily for maintenance.
- GHK-Cuconf 90%pending
GHK-Cu 2 mg subcutaneous daily for 30 days for skin and connective tissue.
- KPVconf 90%pending
KPV 500 mcg subcutaneous daily, or 500 mcg orally twice daily for gut-directed support, for 8 weeks.
- MOTS-cconf 90%pending
MOTS-c 10 mg subcutaneous three times weekly for 4 weeks.
- LL-37conf 90%pending
LL-37 50 mcg subcutaneous every other day;
- Ipamorelinconf 90%pending
CJC-1295 with Ipamorelin is a common synergistic pairing.
- SS-31conf 90%pending
MOTS-c combined with SS-31 may support mitochondrial bioenergetics.
- CJC-1295conf 90%pending
CJC-1295 with Ipamorelin is a common synergistic pairing.
Candidate dosing
8
- CJC-1295conf 82%pending
CJC-1295 100 mcg subcutaneous nightly at bedtime, five nights on and two nights off, for 12 weeks.
dose: 100 mcg · route: subcutaneous · timing: bedtime · duration: for 12 weeks · frequency: nightly
- TB-500 / TB4conf 74%pending
TB-500 / TB4 2 mg subcutaneous twice weekly for 6 weeks.
dose: 2 mg · route: subcutaneous · duration: for 6 weeks · frequency: twice weekly
- BPC-157conf 74%pending
BPC-157 250 mcg subcutaneous twice daily for 4 weeks, then 250 mcg once daily for maintenance.
dose: 250 mcg · route: subcutaneous · duration: for 4 weeks · frequency: twice daily
- MOTS-cconf 74%pending
MOTS-c 10 mg subcutaneous three times weekly for 4 weeks.
dose: 10 mg · route: subcutaneous · duration: for 4 weeks · frequency: weekly
- KPVconf 74%pending
KPV 500 mcg subcutaneous daily, or 500 mcg orally twice daily for gut-directed support, for 8 weeks.
dose: 500 mcg · route: subcutaneous · duration: for 8 weeks · frequency: daily
- GHK-Cuconf 74%pending
GHK-Cu 2 mg subcutaneous daily for 30 days for skin and connective tissue.
dose: 2 mg · route: subcutaneous · duration: for 30 days · frequency: daily
- LL-37conf 66%pending
LL-37 50 mcg subcutaneous every other day;
dose: 50 mcg · route: subcutaneous · frequency: every other day
- Ipamorelinconf 66%pending
Ipamorelin 200 mcg subcutaneous nightly.
dose: 200 mcg · route: subcutaneous · frequency: nightly
Candidate safety
2
- MOTS-cconf 60%pending
Risk of injection-site irritation.
- LL-37conf 60%pending
LL-37 has antimicrobial and immunomodulatory properties and may cause injection-site inflammation.
Candidate monitoring
4
- MOTS-cconf 60%pending
Monitor exercise tolerance and follow-up labs.
- TB-500 / TB4conf 60%pending
Follow-up labs should include a comprehensive metabolic panel.
- TB-500 / TB4conf 60%pending
Monitor IGF-1 and fasting glucose at baseline, week 6, and week 12.
- TB-500 / TB4conf 60%pending
Monitor inflammatory markers including hs-CRP at baseline and every 4 weeks.
Candidate contraindications
4
- LL-37conf 70%pending
Do not use LL-37 in patients with active autoimmune flare without specialist oversight.
- TB-500 / TB4conf 70%pending
These agents may cause transient injection-site reactions and lightheadedness; they are contraindicated in patients with active malignancy.
- KPVconf 70%pending
KPV is generally well tolerated; avoid in pregnancy and lactation due to insufficient safety data.
- TB-500 / TB4conf 70%pending
This combination may cause water retention, flushing, and tingling; use caution in patients with insulin resistance and contraindicated in active cancer.
Candidate synergies
3
- TB-500 / TB4 + BPC-157conf 70%pending
BPC-157 combined with TB-500 / TB4 supports connective-tissue and tendon recovery.
- Ipamorelin + CJC-1295conf 70%pending
CJC-1295 with Ipamorelin is a common synergistic pairing.
- MOTS-c + SS-31conf 70%pending
MOTS-c combined with SS-31 may support mitochondrial bioenergetics.